GleamWall
中文EN

MBIO MUSTANG BIO, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680048 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-51.1%
TTM EPS YoY92.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-43.1%
ROA-20.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets55.1%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio6.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense———————-$664,000
SG&A expense$850,000$946,000$880,000$987,000$957,000$787,000$1.22M-$223,000
Operating income-$1.06M-$1.17M-$1.06M-$670,000-$624,000-$885,000-$253,000-$1.02M
Interest expense———————$1,000
Net income-$964,000-$1.07M-$955,000-$538,000-$468,000-$762,000-$153,000-$952,000
EBITDA-$1.06M-$1.17M-$1.06M-$670,000-$624,000-$885,000-$219,000-$966,000
EPS (basic)-0.14-0.16-0.14—-0.07-0.19-0.05—
EPS (diluted)-0.14-0.16-0.14—-0.07-0.19-0.05—
Weighted avg. shares (diluted)6.74M6.73M6.73M—6.24M4.02M2.86M—
Balance sheet
Cash & equivalents$14.28M$15.15M$16.26M$17.27M$18.98M$12.66M$14.23M$6.84M
Current assets———$17.59M$19.36M$13.05M$14.91M$8.61M
PP&E, net———$0$0$0$0$371,000
Total assets$14.68M$15.61M$16.58M$17.59M$19.36M$13.05M$14.91M$9.31M
Current liabilities$7.95M$7.92M$7.84M$7.91M$9.44M$10.00M$11.15M$12.61M
Total liabilities$8.10M$8.07M$7.99M$8.06M$9.59M$10.15M$11.30M$13.18M
Shareholders' equity$6.59M$7.54M$8.60M$9.53M$9.77M$2.89M$3.61M-$3.87M
Cash flow statement
Operating cash flow-$876,000-$967,000-$1.01M-$1.72M-$818,000-$1.34M-$1.39M-$2.00M
Capital expenditure———————$0
Free cash flow———————-$2.00M
Investing cash flow$0$0$0$0$0$0$1.17M$0
Financing cash flow$2,000-$141,000$0$0$7.14M-$235,000$7.62M$4.94M
Depreciation & amortization$0$0$0$0$0$0$34,000$51,000
Stock-based compensation$2,000$21,000$22,000$23,000$23,000$45,000$38,000$50,000

Free plan shows the latest 8 periods; Pro shows all 46 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.